Systemic vasculitis is a group of inflammatory disorders of blood vessels. Because knowledge of the pathophysiology of these conditions remains incomplete, their treatments are empiric, toxic, and often unsuccessful in inducing durable remissions. Insights derived from this translational research program described by Dr. John Stone, Director of the Johns Hopkins Vasculitis Center, may lead to novel methods of evaluating vasculitis patients. Dr. Stone's mentoring program for junior investigators interested in translational research provides access to a large database of well-characterized patients with vasculitis, outstanding institutional resources for clinical research training, committed mentoring, well-established collaborations within and outside of Johns Hopkins, and a research infrastructure that is essential to career development. As a programmatic research goal in the context of this application, Dr. Stone will employ current funding and existing collaborations to develop his work in proteomics. His co-investigators in this effort are collaborators at the National Cancer Institute/Food & Drug Administration (NCI/FDA) Clinical Proteomics Program, Dr. Emanuel Petricoin and Dr. Lance Liotta. Funding from the Maryland Arthritis Research Consortium (MARRC) and from the Food & Drug Administration's Office of Orphan Products Development will support these studies. The initial disease focus of this work will be Wegener's granulomatosis, using sera collected in the Wegener's Granulomatosis Etanercept Trial (A multicenter, NIAMS-funded trial in which Dr. Stone is the Principal Investigator). Other areas of research at the Vasculitis Center on which young investigators may choose to focus include: 1) the investigation of novel therapeutic approaches; 2) the role of microbial pathogens in the etiology of vasculitis; and, 3) molecular mechanisms of systemic vasculitis (under co-mentoring arrangements with colleagues whose expertise complements that of Dr. Stone), using patient samples and clinical data from the Vasculitis Center.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24AR049185-03
Application #
6888277
Study Section
Special Emphasis Panel (ZAR1-TAS-D (O1))
Program Officer
Gretz, Elizabeth
Project Start
2003-04-01
Project End
2008-03-31
Budget Start
2005-04-01
Budget End
2006-03-31
Support Year
3
Fiscal Year
2005
Total Cost
$123,511
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Rhee, Rennie L; Davis, John C; Ding, Linna et al. (2018) The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. Clin J Am Soc Nephrol 13:251-257
Berti, Alvise; Warner, Roscoe; Johnson, Kent et al. (2018) Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol 70:1114-1121
Wallace, Zachary S; Miloslavsky, Eli M; Cascino, Matthew et al. (2017) Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken) 69:1004-1010
Clain, J M; Hummel, A M; Stone, J H et al. (2017) Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis. Clin Exp Immunol 188:174-181
Fussner, Lynn A; Hummel, Amber M; Schroeder, Darrell R et al. (2016) Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. Arthritis Rheumatol 68:1700-10
Unizony, Sebastian; Villarreal, Miguel; Miloslavsky, Eli M et al. (2016) Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis 75:1166-9
Miloslavsky, E M; Specks, U; Merkel, P A et al. (2015) Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis Rheumatol 67:1629-36
Geetha, Duvuru; Specks, Ulrich; Stone, John H et al. (2015) Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol 26:976-85
Tomasson, Gunnar; Davis, John C; Hoffman, Gary S et al. (2014) Brief report: The value of a patient global assessment of disease activity in granulomatosis with polyangiitis (Wegener's). Arthritis Rheumatol 66:428-32
Miloslavsky, E M; Specks, U; Merkel, P A et al. (2014) Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 66:3151-9

Showing the most recent 10 out of 32 publications